Physician profile
Michael Snyder
NPI 1285611095
$1,557.31
in general payments reported to CMS, 2019-2025
23 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $179 · 2021: $225 · 2022: $331 · 2023: $282 · 2024: $106 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $521.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $214.58 | 2019-2024 | Monovisc, Orthovisc |
| Heron Therapeutics, INC. | $183.53 | 2022-2023 | Aponvie |
| Elite Orthopedics, LLC | $145.10 | 2020-2024 | |
| Pacira Therapeutics, INC. | $133.81 | 2019-2021 | |
| Lundbeck LLC | $115.41 | 2022-2025 | Vyepti |
| Ferring Pharmaceuticals INC. | $100.54 | 2019-2024 | Euflexxa |
| Bioventus LLC | $82.11 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $74.09 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $71.98 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $68.79 | 2022 | |
| Zimmer Biomet Holdings, INC. | $68.16 | 2020-2023 | Gel-One Cross-Linked Hyaluronate |
| Abbvie INC. | $60.23 | 2022 | |
| Fidia Pharma USA INC. | $58.55 | 2022-2024 | Hymovis, Triluron |
| Biohaven Pharmaceuticals, INC. | $33.14 | 2021 | |
| Sanofi-Aventis U.S. LLC | $32.19 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $22.46 | 2021 | |
| Endo Pharmaceuticals INC. | $18.36 | 2020 | |
| Organogenesis INC. | $16.49 | 2021 | |
| Orthofix Medical, INC. | $16.46 | 2025 | Cervical-Stim |
| Assertio Therapeutics, INC. | $15.83 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.39 | 2021 | |
| Convatec INC. | $11.11 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,576,750.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.